Incidence and risk of hypertension in cancer patients receiving anlotinib: Review and Meta-analysis
10.12206/j.issn.1006-0111.202008069
- VernacularTitle:安罗替尼在治疗癌症患者中高血压的发生率和发生风险：一项系统评价和Meta分析
- Author:
Xiaolan LIAO
1
,
2
;
Ying WANG
3
;
Aiwen HUANG
3
;
Xiuqiang GUO
1
,
2
;
Yanlan LAI
1
,
2
;
Hongtao SONG
4
Author Information
1. Department of Clinical Pharmacy
2. College of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
3. Department of Clinical Pharmacy.
4. Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China.
- Keywords:
anlotinib;
cancer;
VEGFR inhibitors;
hypertension;
Meta-analysis
- From:
Journal of Pharmaceutical Practice
2020;38(6):552-557
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the overall incidence and risk of hypertension in the treatment of cancer patients who receive anlotinib and compare the differences between anlotinib and other VEGFR inhibitors. Methods Pubmed, Embase, Cochrane Library, ASCO, CNKI, Wangfang, VIP and CBM databases were searched. Eligible studies were phase II and III prospective clinical trials on cancer patients who received anlotinib and had the hypertension data available. Meta-analysis for the incidence and risk of anlotinib was performed by using R software (version 3.6.0). SPSS software (version 26.0) was used to compare the difference between anlotinib and other VEGFR inhibitors. Results A total of 1387 cancer patients from 13 clinical trials were included in the Meta-analysis. The overall incidences of all grade and high grade hypertension in cancer patients who received anlotinib were about 47.1% (95%CI: 37.7%−56.6%) and 10.6% (95%CI: 7.4%−14.2%). The use of anlotinib was associated with significantly increased risk of all grade (RR=5.58, 95%CI: 2.29−13.60, P<0.01) and high grade hypertension (RR=27.78, 95%CI: 3.56−216.86, P<0.01). In addition, the incidence of high grade hypertension associated with anlotinib was similar to axitinib (RR=0.79, 95%CI: 0.61−1.02, P=0.066) and cabozantinib (RR=0.87, 95%CI: 0.67−1.13, P=0.290). The incidences of rest of other VEGFR inhibitors were lower than that of anlotinib. Conclusions There is a high incidence and significant risk of developing hypertension in cancer patients receiving anlotinib. Adequate monitoring and timely treatment of hypertension is recommended.
